Sinotherapeutics Inc.

Equities

688247

CNE100005PL9

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 28/05/2024 am IST 5-day change 1st Jan Change
9.01 CNY 0.00% Intraday chart for Sinotherapeutics Inc. -3.94% -17.94%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Sinotherapeutics Inc.'s Equity Buyback Plan announced on February 21, 2024. CI
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sinotherapeutics Inc. announces an Equity Buyback for CNY 70 million worth of its shares. CI
Sinotherapeutics Inc. authorizes a Buyback Plan. CI
Sinotherapeutics Gets Nod for Mesalazine Tablets; Shares Drop 7% MT
Sinotherapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Sinotherapeutics' Unit Gets Registration Certificate for Sevelamer Carbonate Tablets MT
Sinotherapeutics Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange A Share Index CI
Sinotherapeutics Inc.(SHSE:688247) added to Shanghai Stock Exchange Composite Index CI
Sinotherapeutics Gets US FDA Nod for Arthritis Drug MT
Sinotherapeutics Signs Product Licensing Deal With US Drugmaker Lannett MT
FDA Greenlights Sinotherapeutics' Mesalazine Enteric-Coated Tablets MT
Sinotherapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sinotherapeutics Drug Selected in China's Centralized Drug Procurement MT
Sinotherapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sinotherapeutics’ Antifungal Drug Added to China’s Medical Insurance Catalog MT
Sinotherapeutics Inc. has completed an IPO in the amount of CNY 424.8358 million. CI
Chart Sinotherapeutics Inc.
More charts
Sinotherapeutics Inc is China-based company mainly engaged in the research and development, commercial production and sales of pharmaceutical preparations. The Company's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The Company mainly operates in the domestic market and overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 688247 Stock
  4. News Sinotherapeutics Inc.
  5. FDA Greenlights Sinotherapeutics' Mesalazine Enteric-Coated Tablets